0001493152-24-009216.txt : 20240307 0001493152-24-009216.hdr.sgml : 20240307 20240307161521 ACCESSION NUMBER: 0001493152-24-009216 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEPHROS INC CENTRAL INDEX KEY: 0001196298 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 133971809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32288 FILM NUMBER: 24730295 BUSINESS ADDRESS: STREET 1: 380 LACKAWANNA PLACE CITY: SOUTH ORANGE STATE: NJ ZIP: 07079 BUSINESS PHONE: 201.343.5202 MAIL ADDRESS: STREET 1: 380 LACKAWANNA PLACE CITY: SOUTH ORANGE STATE: NJ ZIP: 07079 8-K 1 form8-k.htm
false 0001196298 0001196298 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 7, 2024

 

NEPHROS, INC.

(Exact name of Registrant as Specified in its Charter)

 

Delaware

  

001-32288

  

13-3971809

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

380 Lackawanna Place, South Orange, New Jersey 07079

(Address of principal executive offices, including ZIP code)

 

(201) 343-5202

(Registrant’s telephone number, including area code)

 

n/a

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   NEPH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02.Results of Operations and Financial Condition.

 

On March 7, 2024, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its fourth quarter and fiscal year 2023 financial results. A copy of this press release is furnished herewith as Exhibit 99.1.

 

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Nephros, Inc. Press Release, dated March 7, 2024.

104

   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Nephros, Inc.
     
Dated: March 7, 2024 By: /s/ Judy Krandel
    Judy Krandel
    Chief Financial Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call:201 343 5202

 

nephros.com

 

Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million

 

SOUTH ORANGE, NJ, March 7, 2024 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

 

Financial Highlights

 

Fourth Quarter Ended December 31, 2023.

 

  ● Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%
  ● Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022
  ● Adjusted EBITDA from continuing operations was ($0.1 million), compared to ($0.5 million) in the fourth quarter of 2022, an improvement of 89%

 

Year-End 2023

 

  ● Net revenue from continuing operations was $14.2 million, compared with $10.0 million in 2022, up 43%
  ● Net loss from continuing operations was ($1.6 million), compared with ($4.3 million) in 2022
  ● Adjusted EBITDA from continuing operations was ($0.1 million), compared with ($2.4 million) in 2022, an improvement of 97%

 

“2023 was an exciting year for Nephros. With freshly streamlined operations and a refocus on filtration, we grew sales 43% for the full year,” said Robert Banks, President and Chief Executive Officer. “Additionally, new water management guidance, such as ASHRAE 514, has enabled our expanded salesforce to propel Nephros solutions to the front of the line within healthcare facilities. We believe our infection control water filters are well-positioned to fulfill the latest directive recommendations and serve broadened customer needs.”

 

“In my view, our ability to leverage the current regulatory landscape has been a significant driver of growth, as well as our active engagement of new partners and strengthening of existing relationships,” remarked Mr. Banks. “Further, we have enacted a series of deliberate and transformative operational improvements to our supply chain management and consolidated expansion of our corporate footprint. Among these improvements was the opening of our new warehouse space in the fourth quarter, which has enabled us to increase delivery efficiency while supporting growing sales and solving the challenge of significant inventory expansion. Another enhancement was the extension of our supplier production agreement, which helps ensure an uninterrupted source of product.”

 

Mr. Banks continued, “I am very excited about the momentum we have built and am buoyed by the tailwinds created as a result of more stringent water safety standards along with heightened awareness of microbiological proliferation. I look forward to sharing future products, tools and key partnerships as they develop.”

 

Financial Performance for the Fourth Quarter and Year Ended December 31, 2023

 

Net revenue from continuing operations for the year ended December 31, 2023 was $14 million, compared with $10 million in 2022, an increase of 43%. Net revenue for the fourth quarter of 2023 was $3.3 million, compared with $2.6 million in the fourth quarter of 2022, an increase of 27%.

 

1

 

 

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call:201 343 5202

 

nephros.com

 

Cost of goods sold for the year ended December 31, 2023 was $5.8 million, compared with $5.2 million in 2022, an increase of 11%. Cost of goods sold for the fourth quarter of 2023 was $1.2 million, compared with $1 million in the fourth quarter of 2022, an increase of 18%.

 

Gross margin for the year ended December 31, 2023 was 59%, compared with 47% in 2022. Gross margin for the fourth quarter of 2023 was 62%, compared with 59% in the fourth quarter of 2022.

 

Selling, general and administrative expenses for the year ended December 31, 2023 were $8.9 million, compared with $7.6 million in 2022, an increase of 17%. Selling, general and administrative expenses for the fourth quarter of 2023 were approximately $2.4 million, compared with $1.8 million in 2022, an increase of 35%.

 

Research and development expenses for the year ended December 31, 2023 were $0.9 million, compared with $1.3 million in 2022 a decrease of 30%. Research and development expenses for the fourth quarter of 2023 were $0.2 million, compared with $0.4 million in the fourth quarter of 2022, a decrease of 42%.

 

Depreciation and amortization expenses for the year ended December 31, 2023 were approximately $214,000, compared with approximately $218,000 in 2022, a decrease of 2%. Depreciation and amortization expenses for the fourth quarter of 2023 were approximately $51,000, compared with approximately $56,000 in the fourth quarter of 2022, a decrease of 9%.

 

Net loss from continuing operations for the year ended December 31, 2023 was ($1.6 million), compared with a net loss of ($4.3 million) in 2022, a 63% decrease in loss. Net loss from continuing operations for the fourth quarter of 2023 and 2022 was approximately ($0.7 million) respectively.

 

Adjusted EBITDA loss from continuing operations for the year ended December 31, 2023 was ($0.1 million), compared with ($2.4 million) in 2022. Adjusted EBITDA loss from continuing operations for the fourth quarter 2023 was approximately ($0.1 million), compared with approximately ($0.5 million) in the fourth quarter of 2022.

 

As of December 31, 2023, Nephros had cash and cash equivalents of approximately $4.3 million, compared to $3.6 million as of December 31, 2022, and remains debt free.

 

Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures

 

Adjusted EBITDA loss from continuing operations is calculated by taking net loss from continuing operations calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation, amortization, non-cash inventory impairments, and write-offs, and non-cash compensation. The following table presents a reconciliation of Adjusted EBITDA loss from continuing operations to net loss from continuing operations, the most directly comparable GAAP financial measure, for the fourth quarter of the 2023 and 2022 fiscal years:

 

2

 

 

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call:201 343 5202

 

nephros.com

 

 

(unaudited)
                     
2023  Three Month Period Ended   Annual 
   3/31/2023   6/30/2023   9/30/2023   12/31/2023   Totals 
                     
Net loss from continuing operations   (306)   (433)   (182)   (654)   (1,575)
                          
Adjustments:                         
Depreciation of property and equipment   10    10    9    10    39 
Amortization of other assets   44    44    46    41    175 
Interest expense   1    -    -    1    2 
Interest income   (12)   (13)   (11)   (28)   (64)
Non-cash stock-based compensation   319    194    149    390    1,052 
Non-cash inventory impairments   91    15    -    189    295 
                          
Adjusted EBITDA loss from continuing operations   147    (183)   11    (51)   (76)

 

(unaudited)
                     
2022  Three Month Period Ended   Annual 
   3/31/2022   6/30/2022   9/30/2022   12/31/2022   Totals 
                     
Net loss from continuing operations   (1,561)   (747)   (1,250)   (719)   (4,277)
                          
Adjustments:                         
Depreciation of property and equipment   8    20    12    12    52 
Amortization of other assets   47    41    44    44    176 
Interest expense   7    6    4    3    20 
Interest income   (2)   (1)   (4)   (7)   (14)
Non-cash stock-based compensation   254    258    225    207    944 
Non-cash inventory impairments   49    59    665         773 
Other non-cash items   -    (38)   -    -    (38)
                          
Adjusted EBITDA loss from continuing operations   (1,198)   (402)   (304)   (460)   (2,364)

 

Nephros believes that Adjusted EBITDA loss from continuing operations provides useful information to management and investors regarding certain financial and business trends relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA loss from continuing operations in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA loss from continuing operations is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’ financial statements. In addition, Adjusted EBITDA loss from continuing operations is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA loss from continuing operations. To compensate for these limitations, management presents Adjusted EBITDA loss from continuing operations in connection with net loss from continuing operations, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA loss from continuing operations to net loss from continuing operations and not to rely on any single financial measure to evaluate the business.

 

3

 

 

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call:201 343 5202

 

nephros.com

 

Conference Call Today at 4:30pm Eastern Time

 

Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general business overview.

 

Participants may dial into the call as follows:

Domestic access: 1 (844) 808-7106

International access: 1 (412) 317-5285

 

Upon joining, please ask to be joined into the Nephros conference call.

 

An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

 

Alternatively, a replay of the call may be accessed until March 14th, 2024 at 1 (877) 344-7529 or

1 (412) 317-0088 for international callers and entering replay access code: 3916556.

 

About Nephros

 

Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.

 

For more information about Nephros, please visit nephros.com.

 

Forward-Looking Statements

 

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected revenue and cash flows for the quarter and year ended December 31, 2023, expected future revenue growth and the timing of such growth, the effect of new regulations on future revenue growth, Nephros’ ability to appropriately manage product inventory , and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ ability to further develop its sales organization and realize increased revenues, inflationary factors and other economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, which is expected to be filed on or before March 31, 2024. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that it makes, except as may be required by law.

 

Investor Relations Contacts:

 

Kirin Smith, President

PCG Advisory, Inc.

(646) 823-8656

ksmith@pcgadvisory.com

 

Robert Banks, CEO

Nephros, Inc.

(201) 343-5202 x110

robert.banks@nephros.com

 

4

 

 

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call:201 343 5202

 

nephros.com

 

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

   December 31, 2023   December 31, 2022 
ASSETS          
Current assets:          
Cash and cash equivalents  $4,307   $3,634 
Accounts receivable, net   1,496    1,286 
Inventory   2,470    3,153 
Prepaid expenses and other current assets   132    188 
Total current assets   8,405    8,261 
Property and equipment, net   152    116 
Lease right-use-of assets   1,807    984 
Intangible assets, net   381    423 
Goodwill   759    759 
License and supply agreement, net   271    402 
Other assets   86    54 
TOTAL ASSETS  $11,861   $10,999 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Current portion of secured note payable  $-   $71 
Accounts payable   873    740 
Accrued expenses   794    285 
Current portion of lease liabilities   446    316 
Total current liabilities   2,113    1,412 
Equipment financing, net of current portion   -    1 
Lease liabilities, net of current portion   1,390    705 
TOTAL LIABILITIES   3,503    2,118 
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022   -    - 
Common stock, $.001 par value; 40,000,000 shares authorized at December 31, 2023 and 2022; 10,543,675 and 10,297,429 shares issued and outstanding at December 31, 2023 and 2022, respectively   10    10 
Additional paid-in capital   152,754    148,413 
Accumulated deficit   (144,406)   (142,831)
Subtotal   8,358    5,592 
Noncontrolling interest   -    3,289 
TOTAL STOCKHOLDERS’ EQUITY   8,358    8,881 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $11,861   $10,999 

 

5

 

 

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call:201 343 5202

 

nephros.com

 

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

   Twelve Months Ended December 31, 
   2023   2022 
Net revenue:          
Product revenues  $14,110   $9,929 
Royalty and other revenues   128    46 
Total net revenues   14,238    9,975 
Cost of goods sold   5,833    5,244 
Gross margin   8,405    4,731 
Operating expenses:          
Selling, general and administrative   8,911    7,593 
Research and development   873    1,255 
Depreciation and amortization   214    218 
Total operating expenses   9,998    9,066 
Operating loss from continuing operations   (1,593)   (4,335)
Other (expense) income:          
Interest expense   (2)   (20)
Interest income   64    14 
Other (expense) net   (44)   64 
Total other expense:   18    58 
Loss from continuing operations   (1,575)   (4,277)
Net loss from discontinued operations   -    (2,829)
Net loss   (1,575)   (7,106)
Less: Undeclared deemed dividend attributable to noncontrolling interest   -    (276)
Net loss attributable to Nephros Inc. shareholders  $(1,575)  $(7,382)
           
Net loss per common share, basic and diluted from continuing operations  $(0.15)  $(0.42)
Net loss per common share, basic and diluted from discontinued operations   -    (0.28)
Net loss per common share, basic and diluted  $(0.15)  $(0.70)
Net loss per common share, basic and diluted, attributable to continuing noncontrolling interest   -    (0.03)
           
Net loss per common share, basic and diluted, attributable to Nephros, Inc, shareholders  $(0.15)  $(0.73)
Weighted average common shares outstanding, basic and diluted   10,386,018    10,297,134 
           
Comprehensive loss:          
Net loss  $(1,575)  $(7,106)
Other comprehensive loss, foreign currency translation adjustments, net of tax   -    (14)
Comprehensive loss   (1,575)   (7,120)
Comprehensive loss attributable to continuing noncontrolling interest   -    (276)
Comprehensive loss attributable to Nephros, Inc. shareholders  $(1,575)  $(7,396)

 

6

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 neph-20240307.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 neph-20240307_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 neph-20240307_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 07, 2024
Entity File Number 001-32288
Entity Registrant Name NEPHROS, INC.
Entity Central Index Key 0001196298
Entity Tax Identification Number 13-3971809
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 380 Lackawanna Place
Entity Address, City or Town South Orange
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07079
City Area Code (201)
Local Phone Number 343-5202
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol NEPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nephros.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm neph-20240307.xsd neph-20240307_lab.xml neph-20240307_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NEPH", "nsuri": "http://nephros.com/20240307", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "neph-20240307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "neph-20240307_lab.xml" ] }, "presentationLink": { "local": [ "neph-20240307_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://nephros.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nephros.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-009216-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-009216-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001196298 2024-03-07 2024-03-07 iso4217:USD shares iso4217:USD shares false 0001196298 8-K 2024-03-07 NEPHROS, INC. DE 001-32288 13-3971809 380 Lackawanna Place South Orange NJ 07079 (201) 343-5202 false false false false Common stock, $0.001 par value NEPH NASDAQ false